Latest & greatest articles for parkinson

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on parkinson and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for parkinson

1. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson`s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study

Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson`s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study Jerrold L Vitek et al. Lancet Neurol . 2020 Jun . Show details Lancet Neurol Actions . 2020 Jun;19(6):491-501. doi: 10.1016/S1474-4422(20)30108-3. Epub 2020 May 26. Authors , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Department of Neurology, University of Minnesota School of Medicine, Minneapolis

2020 EvidenceUpdates

2. Effects of a core stabilization training program on balance ability in persons with Parkinson`s disease: a randomized controlled trial

Effects of a core stabilization training program on balance ability in persons with Parkinson`s disease: a randomized controlled trial Effects of a Core Stabilization Training Program on Balance Ability in Persons With Parkinson's Disease: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National (...) RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Jun;34(6):764-772. doi: 10.1177/0269215520918631. Epub 2020 Apr 29. Effects of a Core Stabilization Training Program on Balance Ability in Persons With Parkinson's Disease: A Randomized Controlled Trial , , , , , Affiliations Expand Affiliation 1 Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada

2020 EvidenceUpdates

3. Opicapone (Ongentys) - To treat patients with Parkinson’s disease experiencing “off” episodes

Opicapone (Ongentys) - To treat patients with Parkinson’s disease experiencing “off” episodes Drug Approval Package: ONGENTYS U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ONGENTYS Company: Neurocrine Biosciences, Inc. Application Number: 212489 Approval Date: 04/24/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

4. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. (Abstract)

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. We report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient with idiopathic Parkinson's disease. The patient-specific progenitor cells were produced under Good Manufacturing Practice conditions and characterized as having the phenotypic properties of substantia nigra pars compacta neurons; testing (...) in a humanized mouse model (involving peripheral-blood mononuclear cells) indicated an absence of immunogenicity to these cells. The cells were implanted into the putamen (left hemisphere followed by right hemisphere, 6 months apart) of a patient with Parkinson's disease, without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival. Clinical measures of symptoms of Parkinson's disease after surgery stabilized or improved

2020 NEJM

5. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. (Abstract)

Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD).To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD.Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842).57 Parkinson Study Group sites in North America.Patients (...) with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment.5 mg of immediate-release isradipine twice daily or placebo for 36 months.The primary outcome was change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III score measured in the antiparkinson medication "ON" state between baseline and 36 months. Secondary outcomes included time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor

2020 Annals of Internal Medicine

6. Diagnosis and Treatment of Parkinson Disease: A Review. (Abstract)

Diagnosis and Treatment of Parkinson Disease: A Review. Parkinson disease is the most common form of parkinsonism, a group of neurological disorders with Parkinson disease-like movement problems such as rigidity, slowness, and tremor. More than 6 million individuals worldwide have Parkinson disease.Diagnosis of Parkinson disease is based on history and examination. History can include prodromal features (eg, rapid eye movement sleep behavior disorder, hyposmia, constipation), characteristic (...) movement difficulty (eg, tremor, stiffness, slowness), and psychological or cognitive problems (eg, cognitive decline, depression, anxiety). Examination typically demonstrates bradykinesia with tremor, rigidity, or both. Dopamine transporter single-photon emission computed tomography can improve the accuracy of diagnosis when the presence of parkinsonism is uncertain. Parkinson disease has multiple disease variants with different prognoses. Individuals with a diffuse malignant subtype (9%-16

2020 JAMA

7. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study Apomorphine Sublingual Film for Off Episodes in Parkinson's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Neurol Actions 2019 Dec 6 [Online ahead of print] Apomorphine Sublingual Film for Off Episodes in Parkinson's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborator CTH-300 Study investigators

2020 EvidenceUpdates

8. Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. Full Text available with Trip Pro

Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. The goal of this study was to validate an objective method of measuring levodopa induced dyskinesia in Parkinson's disease (PD).To characterize agreement between the clinician-based measure and a force plate, we assessed dyskinesia in PD subjects participating in a randomized and blinded clinical trial of an adenosine A2A anatagonist. Convergent validity and intra-class correlations were evaluated between

2019 Movement disorders clinical practice Controlled trial quality: uncertain

9. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Full Text available with Trip Pro

Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinson disease (PD

2019 Movement disorders clinical practice Controlled trial quality: uncertain

10. Istradefylline (Nourianz) - Parkinson's disease

Istradefylline (Nourianz) - Parkinson's disease CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022075Orig1s000 CLINICAL REVIEW(S) (b) (4) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/istradefylline CLINICAL REVIEW Application Type NDA Application Number(s) 022075 Priority or Standard Class 2 Resubmission Submit Date(s) February 27, 2019 Received Date(s) February 27, 2019 PDUFA Goal Date August 27, 2019 Division/Office DNP Reviewer Name(s) Natalie Branagan, MD Review (...) Completion Date August 26, 2019 Established/Proper Name Istradefylline (Proposed) Trade Name Nourianz Applicant Kyowa Kirin Inc Dosage Form(s) Tablets Applicant Proposed Dosing Administer 20 mg orally once daily. The dose may be increased Regimen(s) to 40 mg once daily based on Applicant Proposed Adjunctive treatment to levodopa/carbidopa in adult patients Indication(s)/Population(s) with Parkinson’s disease experiencing “OFF” episodes. Recommendation on There do not appear to be safety concerns

2019 FDA - Drug Approval Package

11. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial Full Text available with Trip Pro

Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial High-intensity aerobic exercise might attenuate the symptoms of Parkinson's disease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson's disease with mild (...) disease severity who were on common treatment regimes.In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary patients with Parkinson's disease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands. Patients were made aware of the study either by their treating neurologist or via information in the waiting room. Patients could also contact the study team via social media. We included patients aged 30-75 years with a Hoehn and Yahr stage of 2

2019 EvidenceUpdates

12. Levodopa (Inbrija) - Parkinson’s disease

Levodopa (Inbrija) - Parkinson’s disease Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/452546/2019 EMEA/H/C/004786 Inbrija (levodopa) An overview of Inbrija and why (...) it is authorised in the EU What is Inbrija and what is it used for? Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement). Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase. Inbrija contains the active substance

2019 European Medicines Agency - EPARs

13. Canadian guideline for Parkinson disease

Canadian guideline for Parkinson disease APPENDIX 1: CANADIAN GUIDELINE FOR PARKINSON DISEASE, 2 ND EDITION www.parkinson.ca www.ParkinsonClinicalGuidelines.ca Parkinson-final-E.indd 1 2019-09-05 2:39 PMNote: This full version of the Canadian Guideline for Parkinson Disease has been copyedited to be consistent with the summary article published in CMAJ, but has not been peer reviewed. English printed: 978-1-897490-48-8 English electronic: 978-1-897490-49-5 Parkinson-final-E.indd 2 2019-09-05 2 (...) :39 PMTABLE OF CONTENTS Parkinson-final-E.indd 3 2019-09-05 2:39 PMINTRODUCTION ________________ 6 COMMUNICATION ____________ 12 DIAGNOSIS AND PROGRESSION _______________ 15 TREATMENT _________________ 19 NONMOTOR FEATURES OF PARKINSON DISEASE _______ 28 PALLIATIVE CARE _____________ 36 SUPPLEMENTAL MATERIAL _____ 38 REFERENCES _________________ 51 COMMUNICATION n People with Parkinson disease should be encouraged to participate in choices about their own care. n Communication should be in verbal

2019 CPG Infobase

14. Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease

Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease | Report | National Health Care Institute You are here: Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease Search within English part of National Health Care Institute Search Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

2019 National Health Care Institute (Zorginstituut Nederland)

15. Safinamide (Onstryv) - idiopathic Parkinson's disease

Safinamide (Onstryv) - idiopathic Parkinson's disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

16. Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Full Text available with Trip Pro

Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson disease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined (...) effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of Parkinson Disease, Movement Disorders and Brain Injury Rehabilitation

2019 EvidenceUpdates

17. Randomized trial of care management to improve Parkinson disease care quality (Abstract)

Randomized trial of care management to improve Parkinson disease care quality To test effects on care quality of Chronic Care Model-based Parkinson disease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only

2019 EvidenceUpdates

18. Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Full Text available with Trip Pro

Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinson disease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, Parkinson Disease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate

2019 EvidenceUpdates

19. Bright light therapy for depression in Parkinson disease: A randomized controlled trial (Abstract)

Bright light therapy for depression in Parkinson disease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinson disease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic

2019 EvidenceUpdates

20. Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. (Abstract)

Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. Deficits in step-to-step symmetry and trunk muscle activations have been linked to falls in Parkinson disease. Given such symptoms are poorly managed with anti-parkinsonian medications, alternate therapies are needed. This blind phase II randomized controlled trial sought to establish whether exercise can improve step-to-step symmetry in Parkinson disease.Twenty-four Parkinson disease (...) , active interventions seem more suited to increasing independence and quality of life for people with Parkinson disease.Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to do the following: (1) Describe the effect deficits in trunk muscle function have on gait in individuals with Parkinson disease; (2) Identify the benefits of targeted trunk exercises on step-to-step symmetry

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain